Plain-English translation of NCT03601702 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is tracking the safety and effectiveness of the EmboTrap II device, which is used to remove blood clots from major blood vessels in the brain during emergency stroke treatment. Doctors will use this device to restore blood flow to the brain in patients who arrive at the hospital within 12 hours of having a stroke. The study will follow at least 100 patients to see how well the treatment works and whether it causes any complications.
When a large blood vessel in the brain is blocked by a clot during a stroke, time is critical—every minute counts to restore blood flow and prevent permanent brain damage. This study exists to confirm that the EmboTrap II device is safe and effective when used as the first-choice treatment for this life-threatening emergency.
You likely qualify if…
You likely don't qualify if…
As a participant, you will receive emergency clot removal treatment using the EmboTrap II device as part of your acute stroke care—this is the standard treatment your doctors recommend for your condition. After the procedure, you will have a follow-up medical visit within 1 to 10 days to check on your recovery and monitor for any complications. Your medical information and outcomes will be recorded in a registry to help doctors understand how well this device works for stroke patients like you.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Sponsor
Niguarda Hospital
Collaborators
Neuravi Limited
Enrollment target
~100 participants
Started
January 2022
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Edoardo Boccardi, MD
Niguarda Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.